实际上,辉瑞最早跟进减肥药开发的药企之一。辉瑞先是开了3款口服小分子GLP-1受体激动剂:Lotiglipron、Danuglipron(每日口服2次制剂)和Danuglipron(每日口服2次制剂)。但这三款管线相继失败了。Lotiglipron失败于2023年6月的“肝转氨酶升高"安全信号,Danuglipron(每日口服2次制剂)失败于2023年12月的耐受性问题,Danuglipron(...
Source Link实际上,辉瑞最早跟进减肥药开发的药企之一。辉瑞先是开了3款口服小分子GLP-1受体激动剂:Lotiglipron、Danuglipron(每日口服2次制剂)和Danuglipron(每日口服2次制剂)。但这三款管线相继失败了。Lotiglipron失败于2023年6月的“肝转氨酶升高"安全信号,Danuglipron(每日口服2次制剂)失败于2023年12月的耐受性问题,Danuglipron(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.